NYSE · BDX
Becton, Dickinson and Company
Healthcare · Medical - Instruments & Supplies
$198.91▼ 0.75% ($1.51)at close
As of 4:00 PM ET
Valuation
Cash-flow DCF
Verdict: fairly priced. Price between Bear and Base.
The price holds with free cash flow shrinking 3.6% a year for 5 years. Our scenarios assume −5.7–22.6%.
That's below its past 10-year pace of 7.6%.
Value per share
Base case
$374.29
Price used $198.91 is 47% below this
USD · TTM ending Jun 30, 2026 · Price Oct 23, 8:00 PM UTC
FCFF base normalized by replacing latest capex with the company's trailing median capex-to-revenue ratio.
2 more notes
Historical FCFF CAGR and the default growth rates are taken from the raw historical series. The valuation base is normalized for the current-period DCF.
Market beta (0.28) is below the minimum default of 0.5 — short lookback windows can understate systematic risk. Beta floored at 0.5 for default assumptions; adjust manually if needed.
Free cash flow each value needs
Free cash flow today $2.7B. The price needs $2.7B by 2036. Base case: $4.7B. At its recent pace: $5.6B. Bear to Bull: $2.4B to $13.3B.
Free cash flow today $2.7B. The price needs $2.7B by 2036. Base case: $4.7B. At its recent pace: $5.6B. Bear to Bull: $2.4B to $13.3B.
Free cash flow in 2036
today $2.7B
−$2Bless than the Base case
Value per share · Base case
$374.29
Price $198.91
47% below this
- Stage 1 growth, yrs 1–5
- 7.6%
- Stage 2 growth, yrs 6–10
- 4.2%
- Discount rate
- 6.0%
FCFF base normalized by replacing latest capex with the company's trailing median capex-to-revenue ratio.
2 more notes
Historical FCFF CAGR and the default growth rates are taken from the raw historical series. The valuation base is normalized for the current-period DCF.
Market beta (0.28) is below the minimum default of 0.5 — short lookback windows can understate systematic risk. Beta floored at 0.5 for default assumptions; adjust manually if needed.
USD · TTM ending Jun 30, 2026 · Price Oct 23, 8:00 PM UTC
What each scenario assumes. Click a column to start from it.
Price vs Fundamentals
Why The Stock Is Moving
What changed
The stock rose 35.64% over the last year. Revenue declined 2.56% over the trailing twelve months. Operating margin moved from 11.7% to 9.83%. Free cash flow grew 2.2% over the trailing twelve months.
What the market seems to be pricing
The stock has moved higher against modestly weakening underlying metrics. The operating data does not yet tell a clear story — the move may reflect sentiment, sector rotation, or macro factors rather than company-specific earnings power.
What would invalidate this read
Operating margin currently stands at 9.83%. A decisive move in revenue — currently down 2.56% — would be the clearest signal to resolve the ambiguity.
Return analysis
Company profile
Operating globally, Becton, Dickinson and Company (BD) is a prominent enterprise focused on the development, manufacturing, and distribution of a broad spectrum of medical technology.
Market multiples
Stock splits
Every 125 shares became 159
Every 40 shares became 41
Every 1 shares became 2
Every 1 shares became 2
Every 1 shares became 2
Every 1 shares became 2
Profitability & growth
Analyst consensus
16
Buy
17
Hold
1
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Actuals vs estimates by quarter, or any quarter against the same one a year earlier.
Next report
Nov 5, 2026
Q4 FY26 · EPS est $4.07 · Revenue est $5.1B
Same quarter, year over year
FY26 YTD -13.6%Each cell vs the same quarter a year earlier (the cell below) · Q1–Q3 combined $9.04 vs $10.46 · 0 of 3 quarters up
Q1
Q2
Q3
Q4
FY total
FY26
—
FY25
FY24
FY23
—
—
—
—
Fiscal year totals
- FY25
- $14.42
- +9.6%
- FY24
- $13.16
- —
Q3 FY26
Reported Aug 6, 2026 · Latest
HoverTap a cell to inspect
Actual
$3.23
Estimate
$3.14
Year over year
-12.2%
Vs prior quarter
+11.4%
Institutional Sentiment
Becton, Dickinson and Company · BDX
From Form 13F filings (managers with $100M+). Filings land up to 45 days after quarter end — read this as positioning context, not live fund flow.